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analyzed (59 for allograft and 75 for autograft). Thirty-eight
bacterial isolates from blood of 34 patients (25.3%; 20
patients for allograft and 14 for autograft) were reported.
Patients with allogenic HSCT had more frequent BSI (odds
ratio 2.23, p ¼ 0.047) compared to those with autologous
HSCT. BSI of autologous HSCT were reported earlier
compared to those of allogenic HSCT (mean 12.13.4 vs.
26.518.5 days, p ¼ 0.007). HSCT in patients with AML (p ¼
0.029), no use of antibiotics from conditioning (p < 0.001),
and elevated CRP (p ¼ 0.001) were independently associated
with higher incidence of BSI in whole patient population.
Among 59 patients with allogenic HSCT, HSCT > 180 days
after diagnosis (p ¼ 0.035), elevated CRP (p ¼ 0.018), lower
serum albumin (p¼ 0.033), and acute GVHD G2 (p¼ 0.015)
showed relation to BSI in multivariate analysis. As for 75
patients with autologous HCT, only no antibiotics use (p ¼
0.007) and elevated CRP (p ¼ 0.031) were independent risk
factors of BSI. BSIs after allograft was more fatal: 7 of 20
patients with allograft (35%) died of BSI whereas only 1 of 14
patients who underwent autologous HSCT expired.
Conclusion: Except pre-transplant serum CRP elevation,
allogenic and autologous HSCT have different risk factors. BSI
with autologous HSCT occurred earlier and showed better
clinical outcomes compared to BSI with allograft. Distinctive
natures of bacterial infection after HSCT between allogenic
and autologous HST should be considered to establish the
best defense strategy against BSI.305
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Detection of galactomannan (GAM) antigen in the serum has
been found to strongly correlate with Invasive Aspergillosis
(IA) in patients undergoing HCT. We prospectively evaluated
the signiﬁcance of serial GAM measurements in 11 patients
undergoing HCT(cohort1) and compared this with 16
patients (cohort2) receiving non-HCT treatment for haema-
tological disorders. GAM values were measured in all
patients on admission and weekly thereafter until discharge.
A CT scan of the chest was done for all patients with two
serial GAM values above 0.5. A throat swab for fungal culture
was sent for all patients at diagnosis and weekly thereafter.
The median age of the entire group was 38 years (range 6 e
74 years). The cohorts did not differ signiﬁcantly in age,
gender or disease distributions. All patients received anti-
fungal prophylaxis with ﬂuconazole in cohort 2 and mould
active azoles in cohort1. The GAM values on admission were
not signiﬁcantly different among two cohorts; however
subsequent GAM values (1.32 vs 0.77, P ¼ .03) were signiﬁ-
cantly higher in cohort 1. The mean, maximum and
minimum values of GAM (GAMmean, GAMmax, GAMmin)
were signiﬁcantly higher in cohort1(P <.05). Two patients in
cohort1 and one patient in cohort2 developed proven IA.
GAM cutoff of 0.5 didnot correlate with mycological or
radiological evidence of IA in either cohort. However a higher
GAMmean (1.92 vs 0.81, P ¼ .03) and GAMmax (3.17 vs 2.69 P
¼ .08) were associatedwith proven IA. Higher GAM values onadmission (1.23 vs 0.54, P ¼ .04) and higher GAMmean (1.54
vs 0.76, P ¼ .009) correlated with higher mortality irre-
spective of evidence of IA. In multivariate analysis, only
GAMmeanwas associated with higher mortality, particularly
in cohort 1. In conclusion, a cut-off value of 0.5 did not
correlate with development of IA in our population, however
a persistently high GAM value in HCT recipients was an
adverse prognostic factor for nonrelapse mortality irre-
spective of evidence of IA.306
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Hematopoietic stem cell transplantation (HSCT) exposes
patients to signiﬁcant physiologic stress. Risk stratiﬁcation
prior to HSCT is routine. Despite limited data supporting the
prognostic beneﬁt, assessment of left ventricular systolic
function and cardiac stress testing are often performed. A
retrospective analysis of 284 allogeneic HSCT performed
from 1999-2000 in 260 patients, all of whom had a pre-HSCT
stress test, is presented. Stress echos, 170, and stress MUGAs,
114, were performed at Memorial Sloan-Kettering or with
outside physicians. Patients who underwent supine bicycle
exercise multiple gated cardiac blood pool imaging (stress
MUGA) or treadmill exercise echo were included, allowing
for assessment of augmentation in left ventricular ejection
fraction with exercise and functional capacity. Stress tests
used standardized exercise protocols (Bruce, modiﬁed Bruce
for stress echo or WHO for supine exercise bicycle). Stress
tests were in reasonable temporal proximity to HSCT, 4661
days prior for stress echo and 3666 days prior for stress
MUGA (not signiﬁcantly different). Average age at transplant
was approximately 55 years and was not statistically
different for patients who had stress echo or stress MUGA,
but was signiﬁcantly older when compared patients who
were transplanted over the same period and for whom only
a rest echo could be identiﬁed in the medical record
(548yrs vs 527yrs, P ¼ .01). Coronary artery disease or at
least one major cardiac risk was identiﬁed in 69% of patients
who underwent stress testing. Two thirds of patients who
had stress tests had leukemia and one third lymphoma. As
measured with stress echo, percent maximum predicted
heart rate (%MPHR), workload (measured in METS), and
percent augmentation in LVEF with exercise did not correlate
with ICU admission, in-hospital death or death within one
year. Decreased exercise time and decreased rest LVEF both
correlated signiﬁcantly with in-hospital death (ET 63min vs
72min, P ¼ .01 and rest LVEF 577% vs 627%, P ¼ .01), but
neither correlated with ICU admission or death at one year.
Correlation with stress MUGA was weaker with decreased
workload (measured in WATTs) correlating with in-hospital
death (5925WATTs vs 7630WATTs, P ¼ .03), but without
correlation with ICU admission or death at one year. Other
stress MUGA parameters (%MPHR, rest LVEF, percent
augmentation in LVEF, exercise time) had no signiﬁcant
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within one year of transplant. Most stress test parameters
correlate poorly with outcomes of HSCT. Routine stress
testing is unlikely to be of signiﬁcant prognostic value. Stress
echocardiogram is of somewhat more value than stress
MUGA given that rest LVEF and exercise time correlate with
in-hospital death, but a standardized evaluation of exercise
capacity in the clinic and rest echo may be adequate sub-
stitutes.307
Population Pharmacokinetic Study of a Test Dose
Busulfan Patients Undergoing Hematopoietic Stem Cell
Transplantation
Iracema Esteves Nogueira 1, Juliana Fernandes 2,3,
Eduardo K. Sugawara 4, Jose Salvador de Oliveira 5,
Roseane Gouveia 6, Morgani Rodrigues 7, Daniele Porto Barros 8,
Mariane Pereira Diniz 9, Fabio P. de Souza Santos 4,
Andreza Feitosa Ribeiro 7, Jairo J.N. Sobrinho 4,
Sandra Saemi Nakashima 4, Marcos de Lima 10,
Nelson Hamerschlak 4, Fabio R. Kerbauy 4,5. 1 UNIFESP
(Universidade Federal de São Paulo), Brazil; 2 Onco-
Hematology Unit, Instituto da Criança - HC - FMUSP, Sao Paulo,
Brazil; 3 Hospital Israelita Albert Einstein, Brazil; 4 Hematology
and Bone Marrow Transplantation Dept, Hospital Israelita
Albert Einstein, Brazil; 5 Hematology and Bone Marrow
Transplantation Dept, UNIFESP (Universidade Federal de Sao
Paulo), Brazil; 6 Pediatric Bone Marrow Transplantation Center,
Instituto de Oncologia Pediatrica, São Paulo, Brazil;
7 Hematology and Bone Marrow Transplantation Dept, Hospital
Israelita Albert Einstein, Sao Paulo, Brazil; 8 Instituto de
Oncologia Pediátrica, São Paulo, Brazil; 9 Clinical Research
Center, Instituto de Oncologia Pediátrica, São Paulo, Brazil;
10 Department of Medicine - Bone Marrow Transplant Program,
Case Western Reserve University, Cleveland
Introduction: Busulfan (bu) is one of the most used
chemotherapy in conditioning regimens for patients
submitted to hematopoietic cell transplantation (HCT). As Bu
pharmacokinetic (PK) is widely variable, dose adjustment
according to patient PK has been shown to minimize toxic-
ities improving clinical outcome. Usually, PK is calculated
from blood samples collected after the ﬁrst Bu dose, guiding
adjustment of following doses. Although this method has
shown to be reliable, it can be difﬁcult to perform PK in an
optimal time frame. Therefore, using a test dose before HCT
can optimize this method, potentially given more accurate
dose adjustment. Bu test dose has been used with Bu iv
formulation, but little is knownwith oral Bu. In countries like
Brazil where oral Bu is still been used because of cost issues
an optimal drug administration should be developed.
Objectives: To validate the use of oral Bu test dose by
comparing PK from dose test and ﬁrst conditioning regimen
dose.
Methods: 19 patientes were enrolled. Median age was 28
year (range, 4-56). 4 (21%) patients received autologous HCT
while 19 (79%) allogeneic grafts from MRD or MUD donors.
As conditioning regimens, 1 patient recieved Bu(16)/
Flu(160), 9 Bu(16)/Cy(120), 3 Bu(16)Mel(140), 2 Bu(12)/
Cy(120)/Mel(140) and 4 Bu(12)/Cy(120)/Etoposide(1200).
After oral test dose (1mg/kg) 72 hours before conditioning
regimen, blood samples were collected at 8 time points.
Samples were also collected after the ﬁrst Bu dose (1mg/kg)
during conditioning regimen. Bu concentrations were
measured by HPLC. PK parameters were estimated by using
nonlinear mixed effects model computer program. No Bu
dose adjustment was performed based on test dose.Results: PK parameters were comparable between test dose
and ﬁrst conditioning dose: median Bu Clearance (microMol/
min) was 10115,9 (range: 333,43-18270,4) and 11866,1
(range: 4520,3-15589,2) respectively (P ¼ 0,738); median
concentration steady state (mcg/L) was 0,80 (range: 0,55-
1,59) and 0,76 (range: 0,59-1,23) respectively (P ¼ 0,672);
half life (hours) was 2,85 (range: 1,65-5,61) and 2,65 (range:
1,71-6,09) respectively (P ¼ 0,172). Area under the curve
(AUC) (mcgMol.min) was also comparable showing amedian
of 1174 (range: 799-2328) and 1110 (range: 857-1795)
respectively (P ¼ 0,679). Toxicities was comparable to liter-
ature data: 14 (88%) and 5 (12%) patients developed grades 1
to 3 and grade 4 mucositis respectively; 2 (10%) patients
developed sinuisodal obstruction syndrome (SOS) both
received Bu/Cy/Etoposide protocol. All patients achieved full
donor chimerism. Incidence of grade II-IV acute and exten-
sive chronic GVHD was 55% and 31% respectively. With
a median follow-up of 82 days (range: 18-321) 17 patients
were alive.
Conclusions: A population PK model for oral Bu could be
developed, showing efﬁcacy and safety of oral Bu test dose.308
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Background: Intravenous catheters are widely used in
hematopoietic stem cell transplant (HSCT) patients.
Complications associated with these catheters are frequently
encountered and contribute to morbidity, mortality, and
increased cost of treatment. Studies exploring such compli-
cations in this unique patient population are lacking. We
retrospectively studied infectious and thrombotic catheter-
related complications in acute myeloid leukemia (AML)
patients after undergoing HSCT at the largest tertiary referral
center in Oklahoma.
Methods: AML patients above the age of 18 who had HSCT at
The University of Oklahoma Health Sciences Center between
January, 2000 and June, 2012 were identiﬁed and medical
records were reviewed. Patients were stratiﬁed according to
age, ﬁrst HSCT type and type of catheter(s) present at or after
the ﬁrst HSCT (Hickman, peripherally inserted central cath-
eter (PICC) or infusion port (IP)). First blood stream infection
(BSI) and deep venous thrombosis (DVT) events after the ﬁrst
HSCT were reported (subsequent events were not included).
Statistical analysis was performed using SAS 9.2 software
(SAS Institute Inc.). Fisher's exact test was used to compare
patients in the different groups.
Results: 62 patients were included. Median age at diagnosis
was 44 years. 42 (68%) were males and 20 (32%) were
females. 53 (87%) were White, 4 (7%) Native American and 3
(5%) African American. 26 (43%) had sibling (SIB), 22 (36%)
unrelated donor (URD) and 13 (21%) double cord blood (DCB)
transplant. 56 (93%) had Hickman, 30 (50%) PICC and 7 (12%)
IP. 28 patients had one catheter type only (24 Hickman and 4
PICC). BSI occurred in 37% of all cases. BSI rates according to
the presence or absence of a particular catheter type were
38% vs. 33% for Hickman, 37% vs. 38% for PICC and 43% vs. 36%
for IP. In patients with only one catheter type, BSI rates were
38% for Hickman vs. 50% for PICC (P¼ .9). BSI occurred in 40%
